Disseminated hepatic epithelioid hemangioendothelioma with multiorgan metastases achieving long-term stability with Pazopanib: a case report - Report - MDSpire
Advertisement
Disseminated hepatic epithelioid hemangioendothelioma with multiorgan metastases achieving long-term stability with Pazopanib: a case report
Clinical Report: Long-term Disease Control in Hepatic EHE Treated with Pazopanib
Overview
This report details a case of a 28-year-old male with disseminated hepatic epithelioid hemangioendothelioma (HEHE) treated with pazopanib. Over a 4-year follow-up, the patient exhibited stable disease without significant regression or progression of lesions.
Background
Epithelioid hemangioendothelioma (EHE) is a rare malignant vascular neoplasm, primarily affecting the liver and often presenting with multifocal growth. Due to its unpredictable behavior and lack of standardized treatment guidelines, managing HEHE poses significant challenges for healthcare providers. This case highlights the complexities of diagnosing and treating such rare malignancies within the Palestinian healthcare system.
Data Highlights
No significant regression or progression of lesions was observed during the 4-year follow-up period.
Key Findings
The patient presented with progressive headache and constitutional symptoms.
Diagnostic imaging revealed disseminated disease throughout the body.
Histopathology confirmed neoplastic cells consistent with HEHE.
Pazopanib was initiated as a biological treatment plan.
Stable disease was maintained over a 4-year follow-up period.
Clinical Implications
Healthcare professionals should consider EHE in differential diagnoses for vascular tumors, especially in patients presenting with atypical symptoms. The use of pazopanib may provide a treatment option for managing advanced HEHE, although further studies are needed to establish standardized protocols.
Conclusion
This case underscores the clinical intricacies of managing HEHE and the potential role of pazopanib in achieving long-term disease control. Continued research and case reporting are essential to improve understanding and treatment of this rare malignancy.
